Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats

Ji Woong Jang, Jeong Ho Yun, Kwang Il Lee, Ju Woong Jang, Ui-Won Jung, ChangSung Kim, Seongho Choi, Kyoo Sung Cho

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective. The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2. Study Design. Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks. Results. The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP. Conclusions. rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study.

Original languageEnglish
Pages (from-to)480-487
Number of pages8
JournalOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume113
Issue number4
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Osteogenesis
Phosphate Transport Proteins
hydroxyapatite-beta tricalcium phosphate
Bone and Bones
Control Groups
recombinant human bone morphogenetic protein-2

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Pathology and Forensic Medicine
  • Dentistry (miscellaneous)
  • Radiology Nuclear Medicine and imaging

Cite this

@article{7ee4a0489ca04f00bde7b0a7b9d0dc3e,
title = "Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats",
abstract = "Objective. The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2. Study Design. Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks. Results. The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP. Conclusions. rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study.",
author = "Jang, {Ji Woong} and Yun, {Jeong Ho} and Lee, {Kwang Il} and Jang, {Ju Woong} and Ui-Won Jung and ChangSung Kim and Seongho Choi and Cho, {Kyoo Sung}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.tripleo.2011.04.013",
language = "English",
volume = "113",
pages = "480--487",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "4",

}

Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats. / Jang, Ji Woong; Yun, Jeong Ho; Lee, Kwang Il; Jang, Ju Woong; Jung, Ui-Won; Kim, ChangSung; Choi, Seongho; Cho, Kyoo Sung.

In: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Vol. 113, No. 4, 01.01.2012, p. 480-487.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats

AU - Jang, Ji Woong

AU - Yun, Jeong Ho

AU - Lee, Kwang Il

AU - Jang, Ju Woong

AU - Jung, Ui-Won

AU - Kim, ChangSung

AU - Choi, Seongho

AU - Cho, Kyoo Sung

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Objective. The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2. Study Design. Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks. Results. The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP. Conclusions. rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study.

AB - Objective. The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2. Study Design. Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks. Results. The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP. Conclusions. rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study.

UR - http://www.scopus.com/inward/record.url?scp=84862581854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862581854&partnerID=8YFLogxK

U2 - 10.1016/j.tripleo.2011.04.013

DO - 10.1016/j.tripleo.2011.04.013

M3 - Article

C2 - 22676929

AN - SCOPUS:84862581854

VL - 113

SP - 480

EP - 487

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 4

ER -